Trends in childhood pneumococcal vaccine coverage in Shanghai, China, 2005-2011: a retrospective cohort study

BMC Public Health
Matthew L BoultonAbram L Wagner

Abstract

In China, the pneumococcal conjugate vaccine (PCV7) and the pneumococcal polysaccharide vaccine (PPSV23) are not offered under the government's Expanded Program on Immunization and are instead administered for a fee. PCV7 is more effective and covers more serotypes associated with invasive disease in children, but is also more expensive, than PPSV23. Because of their expense, there is concern that these vaccines, especially PCV7, have low uptake particularly among non-locals, migrants from outside of Shanghai. This paper characterizes the differential coverage of PCV7 and PPSV23 between locals and non-locals in Shanghai, and illustrates coverage trends over time. In this retrospective cohort study, children born between 2005 and 2011 were sampled from the Shanghai Immunization Program Information System. Bivariate and multivariable analyses examined the relationships between demographic characteristics, residency status (non-locals vs locals), and vaccination coverage. PPSV23 coverage (29.8 %) among children over 2 years of age was higher than PCV7 coverage (10.1 %) for locals and non-locals. Uptake of PCV7 increased substantially after children were 2 years of age. Overall, non-local populations had higher PPSV23 coverage (OR:...Continue Reading

References

Sep 15, 2009·Lancet·Katherine L O'BrienUNKNOWN Hib and Pneumococcal Global Burden of Disease Study Team
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Feb 2, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lian XueYonghong Yang
Aug 26, 2010·Population and Development Review·Kam Wing Chan
Mar 6, 2012·Lancet·Peng GongJustin V Remais
Aug 14, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J D Grabenstein, K P Klugman
Jun 27, 2014·Vaccine·Zhiyuan HouYuting Zhang
Sep 27, 2014·The Pediatric Infectious Disease Journal·JoLynn P MontgomeryMatthew L Boulton

❮ Previous
Next ❯

Citations

Oct 1, 2016·Expert Review of Vaccines·Qi LiangFeng-Cai Zhu

❮ Previous
Next ❯

Software Mentioned

SAS
SIPIS
GAVI

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.